Menicon’s Innovative Orthokeratology Lens Trial: A Potential Game-Changer for Vision Correction

Menicon Co ((DE:5FR)) announced an update on their ongoing clinical study.

Menicon Co., Ltd. is spearheading a clinical trial titled ‘A Prospective, Multi-centre, Single-Arm Clinical Trial of Orthokeratology Lenses (MCOK-01) in Subjects With Myopia and Myopic Astigmatism.’ The study aims to evaluate the safety and effectiveness of MCOK-01 lenses in correcting myopia and myopic astigmatism. This trial is significant as it could offer a non-surgical alternative for vision correction, potentially benefiting a large population with these conditions.

The intervention being tested is the MCOK-01, a Rigid Gas Permeable contact lens designed for orthokeratology. These lenses utilize a reverse geometry design and are made from a material with high oxygen permeability, intended to reshape the cornea overnight and correct vision temporarily.

The study follows an interventional design with a single-group model, where all participants receive the investigational treatment. There is no masking involved, and the primary purpose is treatment-focused. Participants will wear the lenses nightly for up to 12 months, with regular follow-up visits to monitor progress.

The study is set to begin recruiting on June 24, 2025, with the primary completion and estimated study completion dates yet to be announced. The last update was submitted on the same date, indicating the trial’s preparatory phase.

This clinical update could positively influence Menicon Co.’s stock performance by showcasing innovation in vision correction solutions. As the trial progresses, investor sentiment may become more optimistic, especially if preliminary results indicate success. Competitors in the vision correction industry will likely monitor these developments closely.

The study is ongoing, with further details accessible on the ClinicalTrials portal.